View this API's:

Patents at Patent & Trademark Office Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… ETHYOL (amifostine) Injection, MedImmune Oncology, NDA 20-221/S-017 3/27/03 4/15/03 4/1/03 ETHYOL (amifostine) Injection, MedImmune Oncology, NDA 20-221/S-015 2/20/02 2/21/02 ETHYOL (amifostine) Injection, 500mg (amifostine anhydrous base), US Bioscience NDA 20-221/S-012 6/24/99 6/25/99 6/25/99 6/22/01 Ethyol Indication: To reduce the incidence of moderate to severe xerostomia in patients undergoing post-ooperative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (see Clinical Studies).   For the latest approval information, locate this drug using this index.